18 studies found for:    pomalidomide | Open Studies | multiple myeloma | Phase 2
Show Display Options
Rank Status Study
1 Recruiting Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Pomalidomide
2 Recruiting Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Dexamethasone
3 Not yet recruiting ACY-1215 in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: ACY-1215 in combination with pomalidomide and dexamethasone
4 Recruiting Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Pomalidomide;   Drug: Dexamethasone
5 Recruiting Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
6 Recruiting Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Condition: Multiple Myeloma
Interventions: Drug: POMALIDOMIDE;   Drug: Dexamethasone
7 Recruiting Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
8 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
9 Recruiting Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone;   Drug: Clarithromycin
10 Recruiting Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: gene expression analysis
11 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
12 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
13 Recruiting Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Romidepsin;   Drug: pomalidomide;   Drug: Dexamethasone
14 Unknown  Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Condition: Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: clarithromycin;   Drug: Pomalidomide
15 Recruiting Pomalidomide and Dexamethasone With Growth Factor Support
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: G-CSF;   Behavioral: Phone Calls
16 Not yet recruiting Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Imnovid (pomalidomide);   Drug: Dexamethasone;   Drug: Endoxan (Cyclophosphamide)
17 Recruiting Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
18 Not yet recruiting A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Condition: Advanced Multiple Myeloma
Interventions: Drug: Filanesib, KSP (Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Indicates status has not been verified in more than two years